Shares of AVITA Medical (NASDAQ:RCEL) slid 14% post-market after the company issued updated 2024 and 2025 revenue guidance. After market close, AVITA (NASDAQ:RCEL) said it now expects to report Q4 ...

Jan 8 (Reuters) - AVITA Medical's Australia-listed shares sank nearly 19% on Wednesday, set for their worst day in 15 months, after the regenerative medicine firm cut its forecast for the fourth ...

We expect Avita’s RECELL to pose a significant challenge to the standard of care for larger burns, currently a skin graft sourced from elsewhere on the patient’s body. We believe Avita will be ...

AVITA Medical's Australia-listed shares sank nearly 19% on Wednesday, set for their worst day in 15 months, after the regenerative medicine firm cut its forecast for the fourth time in five ...

For the quarter ended December 31, 2024, AVITA Medical now expects commercial revenue to be approximately $18.4 million, reflecting growth of around 30% over the same period in 2023. Previously ...

Avita Medical, a regenerative medicine company pitching a spray-on skin to burn patients, says it will miss its revenue forecasts, sending shares sliding by a fifth to just a third of its record $ ...

AVITA Medical receives FDA approval of RECELL GO mini, a new addition to the RECELL Spray-On Skin™ technology platform. VALENCIA, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc ...

(Reuters) - AVITA Medical's Australia-listed shares sank nearly 19% on Wednesday, set for their worst day in 15 months, after the regenerative medicine firm cut its forecast for the fourth time in ...

Avita, which specializes in wound care and skin restoration, anticipates fourth-quarter commercial revenue of approximately $18.4 million. It reflects a 30% year-over-year increase. However ...

Lake Street analyst Brooks O’Neil lowered the firm’s price target on Avita Medical (RCEL) to $14 from $20 and keeps a Buy rating on the shares after the company announced preliminary Q4 ...

VALENCIA, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care ...